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solid organ pancreas transplantation address the deficit
in  β-cell  mass  that  underlies  diabetes,  but  these
therapies  are  of  limited  clinical  utility  due  to  the
shortage of donor organs and the side effects inherent to
the  immunosuppression  that  allo-grafts  require.
However,  recent  research  suggests  that  the  human
pancreas  may  possess  a  significant  regenerative
capacity.  Hence,  new  therapeutic  strategies  seek  to
harness this regeneration to re-establish a functional β-
cell mass that is sufficient to normalize glycemia and
reverse diabetes.
Type 1 Diabetes Mellitus
While the exact nature of the insult remains to be
elucidated, T1DM is characterized by the destruction of
pancreatic β-cells due to T-cell-mediated auto-immune
attack (3). Clinical onset is associated with a residual β-
cell mass comprising approximately 20% that of age-
matched non-diabetic individuals (4). It is at this point
that  the  remaining  β-cell  mass  is  incapable  of
maintaining  normoglycemia,  and  persistent
hyperglycemia occurs.
Thus,  the  current  treatment  for  T1DM  consists  of
insulin  replacement,  either  by  the  administration  of
INTRODUCTION 
Diabetes  mellitus  afflicts  approximately  8%  of
Canadians, with an increasing incidence and prevalence
(1,  2).  Most  will  go  on  to  develop  complications,
including  cardiovascular  disease,  nephropathy,
neuropathy and retinopathy, contributing to over $10
billion per year in health-related costs (2).
While the etiologies differ between type 1 (T1DM)
and  type  2  diabetes  (T2DM),  both  forms  are
characterized by a relative deficit in functional β-cell
mass such that the insulin requirements of the body are
not  met  and  glycemia  is  uncontrolled.  Thus,  current
therapies treat the symptoms of diabetes by normalizing
glycemia,  either  by  improving  the  insulin  secretory
output of the remaining β-cells (insulin secretagogues),
improving  the  response  to  insulin  at  target  tissues
(insulin  sensitizers),  or  replacing  the  missing  insulin
(exogenous insulin). As it stands, only isolated islet and
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Copyright ﾩ 2009 by MJM 51 MJM 2009 12(2): 51-60glucose  challenge  are  decreased  in  T2DM  (22-25).
Thus,  a  normal  β-cell  mass  may  not  necessarily
correlate  with  normal  glucose  tolerance  (26),
suggesting  that  the  β-cell  deficit  in  T2DM  may  be
functional, as opposed to absolute (4, 27-34).
It is for these reasons that the current pharmaceutical
options  for  the  management  of  T2DM  fall  into  two
broad  categories;  those  of  insulin  secretagogues  –
compounds that increase the insulin secretory response
of the β-cell – and insulin sensitizers – compounds that
potentiate the effect of insulin at its target tissues. While
these  medications  are  certainly  useful  in  the
management  of  the  disease,  the  fact  remains  that  a
significant  proportion  of  patients  with  T2DM
eventually  require  exogenous  insulin  due  to  the
progressive  loss  of  β-cell  function  and  increase  in
insulin resistance. 
However, recent data now suggests that T2DM is also
characterized by an absolute deficit in β-cell mass (35,
36).  In  fact,  a  step-wise  decline  in  β-cell  mass  is
observed over the progression from normoglycemia to
impaired fasting glucose to overt diabetes (35). With
respect to the mechanism of this loss of β-cell mass, it
would  appear  that  the  rate  of  β-cell  apoptosis  is
increased in T2DM, while the rate of β-cell formation is
unchanged  (35).  Moreover,  it  seems  that  the
hyperglycemic  hyperlipidemic  environment  that  is
found in T2DM is directly toxic to pancreatic β-cells
(37, 38), further propagating this cycle (39-41). Thus,
interventions designed to either slow the rate of β-cell
apoptosis,  or  stimulate  the  formation  of  new  β-cells
may be of clinical utility in the management of T2DM.
β-Cell Mass
Pancreatic β-cell mass is not a static entity, but rather
is  in  constant  flux,  and  as  such  can  adapt  to  the
prevailing  physiologic  needs  (42,  43).  For  example,
insulin  resistance  associated  with  pregnancy  (44)  or
obesity (4, 35, 45) leads to as much as a doubling of β-
cell  mass.  Conversely,  a  deficit  in  β-cell  mass  is
associated with diabetes (9, 35).
Changes in β-cell mass over time reflect the net effect
of diametrically opposed pathways; those that serve to
increase β-cell mass, and those that serve to decrease it.
Possible β-cell mass expansion pathways include β-cell
hypertrophy and replication, as well as the formation of
new β-cells from non-β-cell sources – neogenesis. Each
of these factors has an equivalent opposing force; β-cell
atrophy and death, via apoptosis or necrosis, as well as
β-cell  dedifferentiation,  all  serve  to  decrease  β-cell
mass.  However,  studies  suggest  that  the  three  main
mechanisms at play in controlling β-cell mass dynamics
are β-cell replication, neogenesis and death (35, 46, 47).
Based  on  these  observations,  Finegood  et  al. (42)
exogenous insulin in a manner that seeks to mimic the
secretory response of β-cells, or by the replacement of
the missing β-cell mass by the transplantation of solid-
organ  pancreas  or  isolated  islets  allo-grafts.
Unfortunately, while exogenous insulin administration
may  delay  or  slow  the  development  of  diabetic
complications,  this  treatment  cannot  prevent  their
occurrence  (5,  6).  Conversely,  solid  organ  pancreas
transplant  represents  the  only  available  means  of
providing long-term glycemic control that prevents, and
even, reverses diabetic complications (7), by way of re-
establishing  an  appropriately  functional  β-cell  mass.
However,  life-long  immunosuppression,  with  all  the
associated  side  effects,  along  with  the  limited
availability  of  cadaveric  donor  organs,  limits  any
transplantation-based  approach.  With  respect  to  islet
transplantation,  it  was  hypothesized  that  the  islets
isolated from one donor organ could be used to treat
several  recipients,  given  that  overt  diabetes  is  only
observed when there is a ≥50% reduction in β-cell mass
(4). However, the attrition associated with the isolation
process results in several donor organs being required
per individual recipient, while the average duration of
graft  function  reaching  only  15  months  in  islet
recipients  (8),  as  compared  to  ten  years  in  pancreas
recipients  (7).  Thus,  none  of  the  currently  available
treatments is ideal.
While it stands to reason that the auto-immune attack
responsible  for  T1DM  would  eventually  result  in  a
complete  loss  of  β-cell  mass,  recent  case  reports  of
elderly individuals with long-standing T1DM indicate
ongoing  β-cell  apoptosis  (9,  10),  suggesting  that
attempts  at  β-cell  regeneration  within  the  native
pancreas  may  persist  throughout  the  duration  of  the
disease. The rate of such regenerative mechanisms is
obviously  eclipsed  by  the  rate  of  β-cell  death  in
individuals  with  T1DM,  but  this  observation  does
suggest nonetheless that the manipulation of rates of β-
cell formation and death could be a possible therapeutic
target in diabetes.
Type 2 Diabetes Mellitus
T2DM  accounts  for  the  vast  majority  of  cases  of
diabetes, and is a heterogeneous disease marked by β-
cell  dysfunction  (11,  12)  combined  with  insulin
resistance  in  target  tissues  (11,  13,  14).  The
pathogenesis of the disease involves both genetic (15)
and environmental factors, and is frequently associated
with obesity (13, 16-18). 
With  respect  to  β-cell  dysfunction,  clinical  studies
have  highlighted  the  impaired  first-phase  insulin
secretion that is common in T2DM (19-21). Moreover,
in vitro studies of isolated human islets indicate that
insulin content and the insulin secretory response to a
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mechanisms of increasing β-cell mass are replication –
the formation of β-cells by the division of pre-existing
β-cells – and neogenesis – the formation of β-cells from
non-β-cell precursors (55-59).
β-Cell Replication
While the adult β-cell turnover rate is low (60), in vivo
and  in  vitro studies  have  determined  that  β-cells
proliferate in response to physiologic concentrations of
relevant  growth  factors  (61-68).  Recent  evidence
suggests  that  β-cell  proliferation  may  function  as  a
compensatory mechanism in T2DM (35, 46), although
proliferating  β-cells  are  also  more  susceptible  to
apoptosis  (69,  70). Thus,  β-cell  replication  is  a  real,
semi-quantifiable component of β-cell mass dynamics,
both  in  the  normal  and  diseased  pancreas.  However,
unbridled cell proliferation is a hallmark of cancer, and
as such care must be taken to ensure a physiologic, self-
limiting level of proliferation.
β-Cell Neogenesis
Although  β-cell  replication  and  neogenesis  are
dynamic  processes,  the  availability  of  detectable
markers of cellular proliferation (71, 72) renders the
quantification  of  cell  replication  much  more
straightforward  than  the  measurement  of  neogenesis.
Recent  advances  in  lineage  tracing  techniques  have
facilitated  the  process,  but  questions  regarding  the
cell(s) of origin and inter-species differences mean that
neogenesis is still a polarizing subject. 
Neogenesis implies that β-cells form from non-β-cell
precursors (56-58), though the source and location of
such  precursors  is  not  specified.  Thus,  the  term
neogenesis could be applied to the formation of β-cells
from intra- or extra-pancreatic stem cells, as well as the
direct or indirect transdifferentiation of other adult cell
types. Regardless of the exact nature of the cell(s) of
origin,  neogenesis  represents  a  means  of  expanding
pancreatic β-cell mass.
Regenerative Factors
A variety of animal models have been developed to
study the mechanisms of islet regeneration, and identify
the  factors  involved.  These  models  include  partial
pancreatic duct obstruction (57, 73) or ligation (74, 75),
partial  pancreatectomy  (58,  76),  chronic  and  acute
glucose  infusion  (77-79),  administration  of  a  β-cell-
specific toxin (80) and transgenic models (81-83), all of
which  are  associated  with  an  endogenous  pancreatic
regenerative  response.  As  such,  researchers  have
screened the regenerating pancreas to identify factors
that  may  regulate  the  response,  as  well  as  general
changes in gene expression (84, 85). 
proposed a simple mass-balance equation to follow the
prevailing trends in β-cell mass: 
d(β-cell mass)/dt = rate β-cell replication + rate β-cell
neogenesis – rate β-cell death.
While β-cell mass is highly dynamic, and represents
the  sum  of  several  processes,  the  methods  for
estimating overall β-cell mass and the rates of change
are  static.  Moreover,  no  current  technology  exists  to
accurately assess these parameters in situ. Thus, studies
of β-cell mass in humans are limited to autopsy cases
and  cadaveric  donor  organs,  with  rates  of  changes
presented as relative, rather than absolute values (35,
36). Nevertheless, these studies provide indications of
these mechanisms in non-diabetic humans, and suggest
the effects of diabetes on the mechanisms that control β-
cell mass. 
As indicated earlier, human diabetes is marked by a
deficit  in  functional  β-cell  mass.  While  patients
suffering from T1DM have a virtual lack of β-cell mass
(4), chronic β-cell apoptosis in individuals with T1DM
suggests  β-cell  neogenesis  is  also  ongoing  (9,  10).
Recent  evidence  also  indicates  that  increased  β-cell
apoptosis also leads to a deficit in β-cell mass in T2DM
(35). This increased β-cell apoptosis is observed in both
lean  and  obese  cases  of T2DM,  while  obese T2DM
individuals do show evidence of increased neogenesis
and  lean  T2DM  individuals  have  increased  β-cell
proliferation  indices,  suggesting  compensatory
mechanisms are intact, but outpaced by β-cell apoptosis
(35).  Thus,  these  findings  suggest  that  regenerative
mechanisms do exist within the human pancreas, and it
may be possible to manipulate the rates of the various
components to affect overall β-cell mass.
Limiting  β-Cell Loss
The  mechanisms  responsible  for  depleting  β-cell
mass are well defined, and are predominated by β-cell
death  (35,  42),  either  in  the  form  of  apoptosis  or
necrosis.  Increased  β-cell  death  is  common  to  both
T1DM  (3)  and  T2DM  (35),  however  efforts  at
controlling this aspect of β-cell mass have been limited.
While the auto-immune nature of T1DM suggests that
attenuation  of  the  immune  response  may  help  to
preserve β-cell mass, results of clinical trials have not
supported this therapeutic avenue (48). Likewise, while
inhibition of β-cell apoptosis would likely be a useful
therapy in T2DM, few agents have any specificity for
pancreatic β-cells (49-52), and systemic administration
of a generic anti-apoptotic agent is simply unfeasible.
Inducing β-Cell Expansion
The mechanisms of increasing β-cell mass are still
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112,  113,  115),  recent  statements  by  researchers
examining  the  in  vivo effects  of  GLP-1  call  into
question a neogenic response (116-120). Nevertheless,
GLP-1  certainly  has  a  role  to  play  in  the  evolving
treatment of diabetes, if not as a neogenic factor then at
least with its capacity to act as a β-cell mitogen and
anti-apoptotic supplementing its activity as an incretin.
Reg Proteins
Given that subtotal pancreatectomy combined with
poly(ADP-ribose)  polymerase  inhibitor  treatment
promotes islet regeneration (121), researchers screening
a cDNA library generated from the regenerating islets
identified a novel protein, termed regenerating protein
(Reg,  now  known  as  RegI)  (122).  It  was  later
determined that while some Reg proteins are expressed
in regenerating islets (123), expression is primarily at
acinar tissue (124).
Reg proteins have been postulated to play a role in
inhibition of pancreatic stone formation (125), bacterial
aggregation  (126),  regulation  of  inflammation  (127,
128)  and  cellular  adhesion  to  extracellular  matrix
components  (129),  among  others.  Most  interestingly,
however, in vivo studies suggest that administration of
RegI  may  be  sufficient  to  induce  pancreatic
regeneration  in  both  surgically-induced  (62)  and
genetic (130-133) models of diabetes. Moreover, RegI-
overexpressing mice have increased islet proliferation,
and  crossing  unto  a  genetic  background  of  diabetes
(NOD) delays the onset of diabetes and increases β-cell
mass (134). RegI-/- animals are not overtly diseased,
although  islet  proliferation  is  reduced  (134).  Reg
proteins are mitogenic to islet and ductal cell lines, as
well as isolated islets and primary duct cultures (135-
137),  and  may  also  have  anti-apoptotic  effects  (128,
138).
While  the  exact  Reg  mechanism  of  action  and
signalling  pathways  are  still  contentious  (139),  it  is
noteworthy  that  Reg  expression  or  activity  has  been
associated with other putative regenerative factors. For
example,  administration  of  a  GLP-1  analogue
upregulates  pancreatic  Reg  expression  prior  to
observation of islet regeneration (85), while the effects
of gastrin may be mediated by Reg expression (140,
141).
Thus, while results are promising, Reg proteins, with
the exception of one, have not elicited much clinical
interest.
Islet Neogenesis-Associated Protein
The Reg proteins can be divided into three general
families; RegI, RegIII and Reg IV (142). The RegIII
subfamily  is  characterized  by  the  presence  of  a  five
Several  novel  therapeutics  have  been  developed
based on these studies, all of which are currently in
clinical trials as novel therapies for diabetes.
Gastrin and Epidermal Growth Factor
Studies  of  the  pancreatic  regenerative  response  to
pancreatic duct ligation (74) noted the upregulation of
gastrin and transforming growth factor-β, a member of
the epidermal growth factor (EGF) family of ligands
(75).  Subsequent  studies  indicated  that  alone,  these
factors  acted  mainly  as  duct  cell  mitogens  (86-88),
whereas  co-administration  or  generation  of  double
transgenic animals led to a significant increase in β-cell
mass (82, 89, 90). It now appears that the role of EGF
ligands  may  be  to  generate  metaplastic  duct-like
structures derived from acinar tissue (91, 92), which
then go on to form islets in response to gastrin (93).  
In  vitro studies  suggest  that  human  tissue  can  be
expanded and differentiated in the same way (94-96).
There  is  also  pathologic  evidence  for  such  an  islet
regenerative  effect  of  gastrin,  as  Zollinger-Ellison
syndrome  –  hypergastrinemia  secondary  to  a
gastrinoma  –  is  associated  with  increased  islet
neogenesis and replication (97, 98). 
Based on the above studies, combination therapy with
gastrin and EGF analogues is currently in clinical trials
(99), although due to the established carcinogenicity of
EGF, more recent trials focus on gastrin and glucagon-
like  peptide-1  (GLP-1)  co-administration  (100).
Nonetheless, preliminary data from phase IIa clinical
trials  indicate  that  EGF  and  GLP-1  analogue  co-
administration improve glycemic control, as reflected
by HbA1c, fasting glucose and glucose tolerance (101).
While  clinically  important  and  suggestive  of
mechanism, these outcomes do not necessarily indicate
an increase in endogenous β-cell mass.
Glucagon-like Peptide-1
GLP-1 is a product of alternative post-translational
modification  of  preproglucagon  (102).  While  β-cells
produce and secrete glucagon, enteroendocrine L-cells
of  the  intestine  produce  GLP-1  (103).  Due  to  their
incretin  and  other  effects  (104),  long-acting  GLP-1
analogues (105) and dipeptidyl peptidase-IV inhibitors
(106) are already available for the treatment of T2DM.
Additionally, however, GLP-1 has been implicated in
islet regeneration (64, 107-113), leading to its study as
a regenerative factor.
Data regarding the regenerative role of GLP-1 and
related  agonists  are  controversial.  There  is  strong
evidence to suggest that GLP-1 receptor activation can
protect β-cells from apoptosis (49-52). There is equally
convincing  evidence  of  a  β-cell  mitogenic  effect  of
GLP-1 (49, 64, 108, 114). However, while there are
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While  the  therapies  currently  available  for  the
management  of  diabetes  are  relatively  successful  at
controlling  the  symptoms  of  this  disease,  the  fact
remains that the underlying cause of these symptoms
goes unaddressed. Thus, the majority of patients with
diabetes will develop secondary complications of the
disease  resulting  in  shortened  lifespan  and  reduced
quality  of  life.  Recent  insights  into  the  etiology  of
diabetes have offered a suggestion as to new therapeutic
opportunities for the treatment of diabetes, namely the
re-establishment  of  a  functional  β-cell  mass  that  is
sufficient for glycemic control. Thus, new therapies are
being designed and tested that seek to re-establish a
significant  population  of  functional  β-cells  in  the
endogenous  pancreas,  either  by  inhibiting  the
destruction  of  pre-existing  β-cells,  or  inducing  the
formation of new  β-cells. However, any therapy that
seeks to manipulate the balance between cell death and
survival,  and  differentiation  and  proliferation,  also
carries with it the risk of carcinogenicity. This risk is of
particular  concern  given  that  the  clinical  interest  in
these novel therapies is not necessarily reflective of our
level of understanding of the mechanisms of control of
β-cell  mass  dynamics.  However,  given  the  inherent
ability  of  the  body  to  manipulate  β-cell  mass  in
response to specific metabolic conditions (4, 35, 42-
45), and a recent report that suggests that the body’s
ability to regulate β-cell mass remains intact even in the
context of external manipulation (47), it would appear
that therapies designed at re-establishing a functional
endogenous β-cell mass possess a significant potential
as novel therapies for diabetes.
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